Pharmacokinetic Profile of Tigilanol Tiglate: Cmax, AUC, and Half-Life in Phase I Studies
A look at published systemic exposure data for intratumoral tigilanol tiglate, what plasma concentration measurements have shown about local versus systemic drug distribution.
Pharmacokinetics — what the body does with a drug after it is administered — is a foundation of any clinical drug programme. For tigilanol tiglate, delivered as an intratumoral injection rather than systemically, the pharmacokinetic story is unusual: the goal is to produce a high local concentration at the tumour site while keeping systemic exposure low. Published Phase I data give us the first quantitative window into how well that design works in humans.
Why Intratumoral Delivery Changes the PK Question
Most pharmacokinetic profiling answers the question: how much drug ends up in the bloodstream, and for how long? Standard parameters include Cmax (peak plasma concentration), Tmax (time to reach Cmax), AUC (area under the concentration-time curve, capturing total exposure), and t½ (elimination half-life). For an oral or intravenous drug, these directly govern dosing intervals and predict systemic side effects.
For intratumoral tigilanol tiglate, systemic plasma concentrations are not the therapeutic target — they are a safety check. The drug is intended to act at the injection site through PKC activation, vascular disruption, and local tissue effects, and minimal systemic absorption is desirable to limit off-target effects. So the PK question is reframed: how much of the injected dose escapes the local tissue compartment and enters circulation, and how quickly is it cleared?
What the First Phase I Data Showed
The published Phase I dose-escalation study of intratumoral tigilanol tiglate in patients with advanced solid tumours, reported by Panizza et al. via QBiotics-led trials, collected serial plasma samples around dosing. The headline observation was low systemic exposure: peak plasma concentrations were modest relative to the injected dose, and the drug appeared to clear from circulation within hours rather than days.
This finding aligned with the therapeutic design hypothesis. The injected drug is largely retained in the tumour and surrounding tissue, where it triggers the rapid local response that the molecule was developed for, without producing a sustained systemic plasma reservoir.
Cmax, AUC, and Half-Life — What the Numbers Suggest
In dose-escalation cohorts, Cmax values rose with injected dose in roughly proportional fashion, but absolute systemic concentrations remained low compared to typical chemotherapy plasma levels. AUC, which integrates concentration over time, was correspondingly small. The estimated terminal half-life observed in plasma was on the order of hours, not days.
What this profile tells researchers is that systemic toxicity related to sustained drug exposure is unlikely to be the dose-limiting factor. Instead, dose limits in the Phase I setting were primarily defined by local tissue effects at the injection site — the same effects that drive the therapeutic response.
Why This Matters for Clinical Trial Design
The PK profile influences how subsequent trial cohorts are structured. Because systemic exposure is brief, retreatment intervals can be shortened relative to drugs with long half-lives. Dose-escalation cohorts could focus on local tolerability rather than cumulative plasma toxicity. And biomarker monitoring for systemic inflammatory response remains a relevant safety check despite the low plasma drug concentrations, because the inflammatory cascade triggered locally can still produce measurable systemic readouts.
Limitations and What's Still Unknown
The published Phase I data come from intratumoral injection in defined tumour types. They do not extrapolate to other delivery routes. There is no published pharmacokinetic profile for oral blushwood berry extract supplements containing tigilanol tiglate among multiple seed constituents, because such products are dietary supplements rather than pharmaceuticals and are not subject to drug-style PK profiling.
This is an important distinction. The pharmacokinetic measurements cited here describe purified tigilanol tiglate injected at a defined dose into a defined site under clinical trial conditions. They do not describe what happens when whole blushwood berry extract is consumed orally as a dietary supplement. Consumer supplements like Blushwood Health's EBC-46 tincture contain a 10:1 whole-seed extract and are positioned within the dietary supplement category, with no claim to deliver clinical pharmacokinetic outcomes.
Reading PK Data Critically
When journalists or marketers cite Phase I "PK data" to support claims about supplement absorption, this is almost always an error. PK profiling for an injectable pharmaceutical and the absorption profile of an oral whole-extract supplement are not the same study. Consumers reading about this category should be careful to distinguish the pharmaceutical research programme (QBiotics, Stelfonta) from the dietary supplement category (blushwood berry extract products) — both are legitimate, but they answer different questions.
This article is for informational purposes only. Statements about dietary supplements have not been evaluated by the Food and Drug Administration. Blushwood berry extract supplements are not intended to diagnose, treat, cure or prevent any disease. Consult a qualified healthcare professional before beginning any supplementation programme.
Citations
2. QBiotics Group — Tigilanol Tiglate clinical programme, accessed 2026.
3. FDA — Stelfonta (tigilanol tiglate) approval for canine mast cell tumours, 2020.
Related Articles
EBC-46 Phase 1 Dose Escalation: First-in-Human Safety Data
